Rarely, dose reduction is necessary
Semaglutide, the active ingredient of Wegovy, is a GLP-1 receptor agonist that helps reduce appetite and regulates blood sugar levels
Do not increase doses faster than prescribed, as this worsens gastrointestinal side effects
Meanwhile, there's one thing common between the two: stopping either Tirzepatide or semaglutide can lead to weight gain if there's no tapering or added healthy lifestyle practices
Topical NSAIDs are preferred over oral NSAIDs, especially in patients with kidney disease, heart failure, or those taking ACE inhibitors, ARBs, or diuretics For patients with more significant symptoms, physical therapy evaluation can be valuable for assessing biomechanics, providing targeted strengthening exercises, and addressing any movement pattern abnormalities that may contribute to joint stress
They concluded: This treatment regimen had no effect on either circulating glucose or insulin